• This multicentre, phase 2, randomized, controlled study of allogeneic haematopoietic stem cell transplantation (allo-HSCT) recipients compared the immunogenicity of two anti- pneumococcal vaccine regimens four doses of 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) (3+1+1 experimental group), and three doses of PCV13 followed by PPSV23 (3+0+1 group). (bvsalud.org)
  • Prevnar 13 (PCV13) is produced by the Wyeth subsidiary of Pfizer and it replaces Prevnar (PCV7), the pneumococcal 7-valent conjugate vaccine (PCV7). (wikipedia.org)
  • The pneumococcal conjugate vaccine (PCV13) and the pneumococcal polysaccharide vaccine (PPSV23) protect against pneumococcal infections. (kidshealth.org)
  • PCV13 protects against 13 types of pneumococcal bacteria, which cause the most common pneumococcal (new-muh-KOK-uhl) infections in kids. (kidshealth.org)
  • GRADE was used to evaluate 13-valent Pneumococcal Conjugate Vaccine (PCV13) for routine use among adults aged ≥65 years. (cdc.gov)
  • The intervention evaluated was a single dose of PCV13 compared to a dose of 23-valent polysaccharide vaccine (PPSV23). (cdc.gov)
  • Evidence used to evaluate efficacy of PCV13 against IPD and pneumococcal pneumonia was from the randomized placebo-controlled trial (RCT) conducted among approximately 85,000 adults aged ≥65 years in Netherlands (CAPiTA). (cdc.gov)
  • The first, which is the pneumococcal conjugate vaccine, or PCV13, guards against 13 strains of the bacteria. (medicalnewstoday.com)
  • While both vaccines offer protection from bacteremia and meningitis, only PCV13 gives protection from pneumonia. (medicalnewstoday.com)
  • CDC guidelines for who should get the PCV13 vaccine include all children under the age of 2 and all people aged 2 and older with certain medical conditions. (medicalnewstoday.com)
  • Infants should receive the PCV13 vaccine at 2, 4, 6, and 12-15 months. (medicalnewstoday.com)
  • In December 2010 PCV13 vaccine replaced PCV7 in the Irish childhood immunisation programme. (hse.ie)
  • The 13-valent pneumococcal conjugate vaccine (PCV13), is also sometimes referred to by the brand name Prevnar. (coloradoallergy.com)
  • The PCV13 is recommended for all babies and children younger than 2 years old and is a part of the standard childhood vaccine schedule. (coloradoallergy.com)
  • In most cases, there should be at least a year's wait between getting the PCV13 and the PPSV23 vaccines. (coloradoallergy.com)
  • The Vietnam Pneumococcal Trial II (VPT-II) will evaluate reduced-dose schedules of PCV10 and PCV13 utilising an unvaccinated control group. (bmj.com)
  • A computer-based cost-effectiveness analysis suggests that use of the 13-valent pneumococcal conjugate vaccine (PCV13) might prevent more pneumococcal disease compared with the current 23-valent pneumococcal polysaccharide vaccine (PPSV23) vaccination recommendations, while remaining economically reasonable, although the authors note that their findings are sensitive to a number of assumptions, according to a study in the Feb. 22/29 issue of JAMA. (infectioncontroltoday.com)
  • The effectiveness of the PCV13 vaccine in preventing NPP in adults is currently unknown. (infectioncontroltoday.com)
  • indirect (herd immunity) effects resulting from childhood PCV13 vaccination were extrapolated based on observed 7-valent pneumococcal conjugate vaccine (PCV7) effects. (infectioncontroltoday.com)
  • With routine vaccine administration at ages 50 and 65 years, it was estimated that PCV13 costs $45,100 per QALY compared with PCV13 substituted in current recommendations. (infectioncontroltoday.com)
  • The researchers note that results were robust in sensitivity analyses and alternative scenarios, except when low PCV13 effectiveness against nonbacteremic pneumococcal pneumonia was assumed or when greater childhood vaccination indirect effects were modeled. (infectioncontroltoday.com)
  • Model estimates of the effect of adult PCV13 would be strengthened by evidence of PCV13 effectiveness against NPP from ongoing clinical trials and availability of data on the indirect effects of childhood PCV13 on adult pneumococcal disease rates, the authors conclude. (infectioncontroltoday.com)
  • For Germany, we have described earlier the distribution of vaccine serotypes covered by the first but no longer available 7-valent pneumococcal conjugate vaccine (PCV7) and the 13-valent conjugate vaccine (PCV13) between 2002 and 2016 in adult patients with CAP enrolled into the prospective multicentre study CAPNETZ [ 8 , 9 ]. (ersjournals.com)
  • PCV7 was replaced by either the 10-valent conjugate vaccine or, mainly, PCV13 in the German infant vaccination programme in 2010. (ersjournals.com)
  • There are three pneumococcal conjugate vaccines (PCV13, PCV15, and PCV20). (stylesubstancesoul.com)
  • PCV13 (pneumococcal conjugate vaccine) protects against 13 of the approximately 90 types of pneumococcal bacteria that can cause pneumococcal disease, including pneumonia, meningitis, and bacteremia. (stylesubstancesoul.com)
  • To prevent pneumococcal disease, there are two types of pneumococcal vaccines: the pneumococcal polysaccharide vaccine (PPSV23) and the pneumococcal conjugate vaccine (PCV13). (stylesubstancesoul.com)
  • Impaired response to 13-valent pneumococcal conjugate vaccine (PCV13) in children with recurrent respiratory infections and chronic cough. (ers-education.org)
  • Both PCV7, PCV10 and PCV13 are licensed for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by the respective vaccine serotypes of S. pneumoniae in infants and children from 6 weeks to 5 years of age. (who.int)
  • In addition, PCV13 is licensed for the prevention of pneumococcal disease in adults >50 years of age. (who.int)
  • BACKGROUND: Although use of the 13-valent pneumococcal conjugate vaccine (PCV13) among children has reduced incidence of pneumococcal disease, a considerable burden of disease remains. (cdc.gov)
  • PCV15 is a new vaccine that contains pneumococcal serotypes 22F and 33F in addition to serotypes contained in PCV13. (cdc.gov)
  • We assumed that vaccine effectiveness (VE) of PCV15 against the two additional serotypes was the same as the VE of PCV13. (cdc.gov)
  • RESULTS: Our base case results found that replacing PCV13 with PCV15 prevented 92,290 additional pneumococcal disease events and 22 associated deaths, while also saving $147 million in costs. (cdc.gov)
  • A supplementary PCV15 dose among children aged 2-5years who were fully vaccinated with PCV13 prevented further pneumococcal disease events and associated deaths but at a cost of more than $2.5 million per QALY gained. (cdc.gov)
  • CONCLUSIONS: A further decrease in pneumococcal disease in conjunction with considerable societal cost savings could be expected from replacing PCV13 with PCV15 within the routine infant immunization program in the United States. (cdc.gov)
  • Thirteen-valent pneumococcal conjugate vaccine (PCV13) was recommended for use in US children in 2010 and for PWH aged 19 years or older in 2012. (cdc.gov)
  • GRADE was used to evaluate 13-valent Pneumococcal Conjugate Vaccine (PCV13) for routine use among immunocompromised children aged 6 through 18 years. (bvsalud.org)
  • When in doubt about the appropriate handling of a vaccine, vaccination providers should contact that vaccine's manufacturer. (cdc.gov)
  • In certain circumstances in which a single vaccine type is being used (e.g., in preparation for a community influenza vaccination campaign), filling a small number (10 or fewer) of syringes may be considered (5). (cdc.gov)
  • Prevnar (PCV7) was approved for use in the United States in February 2000, and vaccination with Prevnar was recommended for all children younger than two years and for unvaccinated children between 24 and 59 months old who were at high risk for pneumococcal infections. (wikipedia.org)
  • Talk to your healthcare professional about pneumococcal vaccination. (nfid.org)
  • For more information, see Pneumococcal Advisory Committee on Immunization Practices Vaccine Recommendations and Centers for Disease Control and Prevention (CDC): Pneumococcal Vaccination . (merckmanuals.com)
  • For detailed information on administering the pneumococcal vaccine to children see CDC: Pneumococcal Vaccination: Summary of Who and When to Vaccinate and CDC: Child and Adolescent Immunization Schedule by Age ). (merckmanuals.com)
  • As for any vaccine PCV vaccination should be postponed in those individuals who have an acute febrile illness. (hse.ie)
  • Prior to vaccination, individuals (or their parents and/or legal representatives) receive Vaccine Information Statements (VIS) prior to getting the vaccine. (hrsa.gov)
  • Vaccination with VAXNEUVANCE may not protect all vaccine recipients. (merck.com)
  • Kenneth J. Smith, MD, MS, of the University of Pittsburgh School of Medicine, and colleagues conducted a study to estimate the effectiveness and cost-effectiveness of pneumococcal vaccination strategies among adults 50 years of age and older. (infectioncontroltoday.com)
  • With no vaccination, the estimated lifetime risk from age 50 years onward for hospitalized NPP was 9.3 percent, for IPD was 0.86 percent, and for death due to pneumococcal disease was 1.8 percent. (infectioncontroltoday.com)
  • Pneumococcal conjugate vaccines (PCVs), which were primarily developed for vaccination of infants under 2 years of age, have significantly decreased invasive pneumococcal diseases worldwide in all age groups by herd protection effects [ 5 , 6 ]. (ersjournals.com)
  • In adults, the German Standing Committee on Immunization (STIKO) recommends the 23-valent pneumococcal polysaccharide vaccine (PPV23) as routine pneumococcal vaccination for all adults of 60 years and above and for all patients with defined chronic comorbidities predisposing to pneumococcal disease, regardless of age. (ersjournals.com)
  • CDC recommends pneumococcal vaccination for all children younger than 2 years old and all adults 65 years or older. (stylesubstancesoul.com)
  • Live, attenuated vaccines should be administered only when an inactivated version does not exist and the risk of the disease clearly outweighs the theoretical risk of vaccination. (hivguidelines.org)
  • Use live, attenuated vaccines only if an inactivated alternative is not available and the risk of disease is greater than the risk of vaccination. (hivguidelines.org)
  • The present data contribute to pneumococcal vaccination public health policies for vulnerable patients, mainly those with comorbidity and the elderly. (bvsalud.org)
  • Up-to-date vaccination for al vaccine-preventable resources of the host country and have been associated diseases (VPDs) is the best way to prevent il ness, with disease outbreaks and the international spread of outbreaks and the international spread of disease. (who.int)
  • The vaccine is given to children as part of the routine vaccination schedule with the first dose of PCV given at the age of 6 weeks or 2 months (depending on the national schedule), followed by 2 doses at one to two months intervals. (who.int)
  • METHODS: We estimated the incremental number of pneumococcal disease events and deaths averted, costs per quality adjusted life-year (QALY) gained, and costs per life-year gained under different vaccination strategies using a probabilistic model following a single birth cohort of 3.9 million individuals (based on 2020 U.S. birth cohort). (cdc.gov)
  • Pneumonia vaccines help prevent invasive pneumococcal diseases. (medicalnewstoday.com)
  • Although the pneumonia shots will not prevent a person from ever getting pneumonia, they may help in reducing cases of invasive pneumococcal diseases. (medicalnewstoday.com)
  • To this end, they are including most common serotypes for preventing invasive pneumococcal diseases in paediatrics. (medgadget.com)
  • The high risk of mortality of invasive pneumococcal diseases has spurred research pertaining to this patient cohort, thereby unlocking new prospects in the pneumonia vaccines market. (medgadget.com)
  • Particularly, progress made in development of vaccines for the development of invasive pneumococcal diseases has also reinforced lucrative avenues to vaccine manufacturers. (medgadget.com)
  • Although Pneumococcal Conjugate Vaccines (PCVs) are available and have significantly reduced the rate of invasive pneumococcal diseases, there is still a need for new vaccines with unlimited serotype coverage, long-lasting protection, and lower cost to be developed. (mdpi.com)
  • Background: Chronic conditions increase the risk of invasive pneumococcal diseases (IPD). (bvsalud.org)
  • The second, which is the pneumococcal polysaccharide vaccine, or PPSV23, guards against 23 strains. (medicalnewstoday.com)
  • It also seems to confer greater protection against invasive pneumococcal disorders than PPSV23. (merckmanuals.com)
  • The second pneumonia vaccine available is the 23-valent pneumococcal polysaccharide vaccine (PPSV23). (coloradoallergy.com)
  • The PPSV23 vaccine has been recommended for prevention of invasive pneumococcal disease (IPD) in adults since 1983, according to background information in the article. (infectioncontroltoday.com)
  • Most studies show that PPSV23 provides some protection against IPD, but studies have reached contradictory conclusions about its ability to prevent nonbacteremic pneumococcal pneumonia (NPP), which causes several hundred thousand illnesses annually in the United States. (infectioncontroltoday.com)
  • VAXNEUVANCE®▼ (pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed)) is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. (msdconnect.co.uk)
  • VAXNEUVANCE®▼ (pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed)) is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older. (msdconnect.co.uk)
  • Pneumococcal conjugate vaccine is a pneumococcal vaccine and a conjugate vaccine used to protect infants, young children, and adults against disease caused by the bacterium Streptococcus pneumoniae (pneumococcus). (wikipedia.org)
  • Prevnar (PCV7) was produced from the seven most prevalent strains of Streptococcus pneumoniae bacteria in the U.S. The bacterial capsule sugars, a characteristic of these pathogens, are linked (conjugated) to CRM197, a nontoxic recombinant variant of diphtheria toxin (from cultures of Corynebacterium diphtheriae). (wikipedia.org)
  • and for the prevention of otitis media (ear infection) caused by 7 of the serotypes of Streptococcus pneumoniae contained in the vaccine for children 6 weeks through 5 years of age. (wikipedia.org)
  • Pneumococcal disease is an infection caused by the bacteria Streptococcus pneumoniae , or pneumococcus. (cnshealthcare.com)
  • Pneumococcal disease is a bacterial infection caused by streptococcus pneumoniae of which there are more than 90 serotypes. (hse.ie)
  • Over the years streptococcus pneumoniae has become resistant to many medications making the treatment of pneumococcal infections much more difficult. (hse.ie)
  • This vaccine contains purified polysaccharide from 23 of the most common capsular types of streptococcus pneumoniae. (hse.ie)
  • Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, as submitted for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults ages 18 years and older. (pfizer.com)
  • The bacteria Streptococcus pneumoniae is responsible for pneumococcal infections causing otitis media, bacteremia, pneumonia, and meningitis. (medgadget.com)
  • KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older. (merck.com)
  • The global prevalence of pneumococcal disease, an infection caused by bacteria called Streptococcus pneumoniae , is evolving. (merck.com)
  • Pneumococcal infections are globally the most frequent vaccine-preventable cause of death [ 1 ], and community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae is the main burden of pneumococcal disease in the elderly [ 2 ]. (ersjournals.com)
  • NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in the vaccine in adults ages 18 years and older. (stylesubstancesoul.com)
  • Background: Antimicrobial resistance in Streptococcus pneumoniae has compromised the effectiveness of therapy for pneumococcal diseases and asymptomatic nasopharyngeal carriers play an important role in transmission of resistant strains. (bvsalud.org)
  • Pneumococcal bacteremia is a blood infection. (cnshealthcare.com)
  • These vaccines protect the body against bacteria that can cause meningitis, bacteremia (blood infection) and pneumonia. (coloradoallergy.com)
  • Pneumococcal polysaccharide vaccine (PPV23): this contains containing 23 serotypes of the pneumococcus, which account for 88% of pneumococcal bacteremia disease and cross-react with other types that causes additional 8% of disease. (who.int)
  • Through reductive amination, the sugars are directly conjugated to the protein carrier CRM197 to form the glycoconjugate. (wikipedia.org)
  • V114 consists of pneumococcal polysaccharides from 15 serotypes conjugated to a CRM197 carrier protein and includes serotypes 22F and 33F, which are commonly associated with invasive pneumococcal disease in older adults worldwide and are not contained in the pneumococcal conjugate vaccine currently licensed for use in adults. (merck.com)
  • Both Prevenar 13 and Prevenar use CRM197 -- an immunological carrier protein with a 20-year history of use in pediatric vaccines. (science20.com)
  • In February 2010, Prevnar 13 was approved in the United States to replace Prevnar (PCV7), the pneumococcal 7-valent conjugate vaccine (PCV7). (wikipedia.org)
  • Prevnar (PCV7) is a heptavalent vaccine, meaning that it contains the cell capsule sugars of seven serotypes of the bacteria S. pneumoniae (4, 6B, 9V, 14, 18C, 19F, and 23F) conjugated with diphtheria proteins. (wikipedia.org)
  • The Prevnar (PCV7) seven-valent formulation (PCV7) contains serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, and resulted in a 98% probability of protection against these strains, which caused 80% of the pneumococcal disease in infants in the U.S. PCV7 is no longer produced. (wikipedia.org)
  • In June 2021, the U.S. Food and Drug Administration (FDA) approved the pneumococcal 20-valent conjugate vaccine, sold under the brand name Prevnar 20 (PCV20), for adults 18 years of age and older. (wikipedia.org)
  • Other solid performers in vaccines include GlaxoSmithKline, which placed five vaccines on the list, and Pfizer, whose vaccine Prevnar 13 topped the list with nearly $4 billion in sales last year. (genengnews.com)
  • The candidate, the company found similar safety profile, as its Prevnar 13, a 13-valent pneumococcal conjugate vaccine. (medgadget.com)
  • The development of pneumococcal conjugate vaccines, in which each of the selected bacterial capsular polysaccharides is coupled to a protein carrier molecule, has been a major advance in the prevention of invasive pneumococcal disease. (who.int)
  • In particular, the recommendations provide guidance on the design of immunogenicity studies that should be performed in order to support the licensure of new pneumococcal conjugate vaccines (including those containing conjugated capsular polysaccharides of serotypes additional to or different from those in already licensed vaccines). (who.int)
  • Adults with certain medical conditions also are at increased risk for invasive pneumococcal disease (IPD). (cdc.gov)
  • A pneumococcal disease outbreak caused by Strepto- in a blood culture from an ill patient incarcerated coccus pneumoniae serotype 12F occurred in a state prison in Alabama, USA. (cdc.gov)
  • Invasive pneumococcal At the time of the outbreak, facility A, a medium-se- disease (IPD) occurs when pneumococcus invades curity state prison, housed 1,276 male inmates across normally sterile sites. (cdc.gov)
  • A clinic within facility A with a ( 4 ), and pneumococcal disease incidence has declined 52-member staff, including 2 nurse practitioners and since the introduction of PCV ( 5 ). (cdc.gov)
  • After waiting for the outcome of a trial underway in the Netherlands, the Centers for Disease Control and Prevention (CDC) recommended the vaccine for adults over age 65 in August 2014. (wikipedia.org)
  • These vaccines are very effective at preventing severe disease, hospitalization, and even death. (kidshealth.org)
  • The pneumococcal vaccines contain only a small piece of the germ and so cannot cause pneumococcal disease. (kidshealth.org)
  • The benefits considered critical outcomes in GRADE included prevention of invasive pneumococcal disease (IPD), pneumococcal community-acquired pneumonia, and hospitalizations due to pneumococcal disease. (cdc.gov)
  • [2] Evidence was not available for the critical outcome of hospitalizations due to pneumococcal disease. (cdc.gov)
  • Combined with invasive pneumococcal disease estimates, it will estimate the impact of polysaccharide conjugate vaccines. (warwick.ac.uk)
  • It's important to prevent pneumococcal disease in adults. (nfid.org)
  • Pneumococcal disease is serious and can be deadly. (nfid.org)
  • Getting pneumococcal vaccines as recommended reduces your chance of contracting and dying from pneumococcal disease. (nfid.org)
  • Are You at Risk for Pneumococcal Disease? (nfid.org)
  • Noninvasive pneumococcal disease includes sinusitis . (medicalnewstoday.com)
  • One dose of PCSV23 helps protect about 50-85 out of 100 healthy adults against invasive pneumococcal disease. (medicalnewstoday.com)
  • Like all vaccines, it works with the body's natural defenses to develop immunity to disease. (cnshealthcare.com)
  • Pneumococcal disease is contagious, meaning it spreads from person to person and causes thousands of infections every year in the United States. (cnshealthcare.com)
  • The good news is that pneumococcal vaccines can help prevent the disease. (cnshealthcare.com)
  • There are many types of pneumococcal disease. (cnshealthcare.com)
  • Pneumococcal pneumonia (lung infection) is the most common serious form of pneumococcal disease. (cnshealthcare.com)
  • Vaccines are directed against many of the serotypes that cause disease. (merckmanuals.com)
  • Certain medical conditions (eg, chronic disorders, immunocompromising conditions, cerebrospinal fluid leaks, cochlear implants) increase the risk of pneumococcal disease. (merckmanuals.com)
  • What is pneumococcal disease? (hse.ie)
  • What are the symptoms of pneumococcal disease? (hse.ie)
  • Who is most at risk of pneumococcal disease? (hse.ie)
  • Pneumococcal disease can lead to significant morbidity and mortality, particularly amongst the very young, the very old, those with impaired immunity and those with anatomic or functional asplenia. (hse.ie)
  • How is pneumococcal disease transmitted? (hse.ie)
  • The decrease in this age group can largely be attributed to a 98% decline in Invasive pneumococcal disease (IPD) due to serotypes covered by PCV7 between 2008 and 2016. (hse.ie)
  • Pneumococcal disease is a very serious disease. (hse.ie)
  • The FDA's acceptance of our application for 20vPnC is yet another significant milestone in Pfizer's continuing efforts to help protect adults against pneumococcal disease," said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research and Development, Pfizer. (pfizer.com)
  • If approved, 20vPnC will cover more serotypes responsible for the majority of pneumococcal disease than any other pneumococcal conjugate vaccine currently licensed or currently in late-stage clinical development. (pfizer.com)
  • The introduction of pneumococcal conjugate vaccines into infant immunization schedules has successfully reduced the incidence of pneumococcal disease caused by vaccine serotypes. (uzh.ch)
  • Demand for prevention of invasive pneumococcal disease has helped shape the approaches for manufacturers. (medgadget.com)
  • For a vaccine to be covered, the Centers for Disease Control and Prevention (CDC) must recommend the category of vaccine for routine administration to children or pregnant women, and it must be subject to an excise tax by federal law. (hrsa.gov)
  • The VIS contains information about the disease(s) prevented by the vaccine. (hrsa.gov)
  • These submissions for V114 help bring us closer to offering more options to help protect against pneumococcal disease. (merck.com)
  • V114 is Merck's investigational 15-valent pneumococcal conjugate vaccine candidate for the prevention of pneumococcal disease in adults and children. (merck.com)
  • V114 previously received Breakthrough Therapy Designation from the FDA for the prevention of invasive pneumococcal disease in pediatric patients 6 weeks to 18 years of age and adults 18 years of age and older. (merck.com)
  • and meningitis (infection of the coverings of the brain and spinal cord), as well as non-invasive pneumonia (when pneumococcal disease is confined to the lungs). (merck.com)
  • While healthy adults can suffer from pneumococcal disease, patient populations particularly vulnerable to infection include older adults such as those 65 years of age and older, people with HIV, and those with certain chronic health conditions. (merck.com)
  • VAXNEUVANCE is indicated in the U.S. for active immunization of adults 18 years of age and older for the prevention of invasive disease caused by the S. pneumoniae serotypes contained in the vaccine. (merck.com)
  • In April 2013, Fengcai Zhu, Deputy Director of the Jiangsu Provincial Center for Disease Prevention and Control, and co-principal investigator of Sinovac's phase III trial on EV71 vaccine, presented data regarding the efficacy and safety of the Company's proprietary EV71 vaccine against HFMD at the 13th Annual World Vaccine Congress & Expo. (sinovac.com)
  • New data from Phase 3 European clinical trials reinforce that Wyeth's (NYSE: WYE) investigational pneumococcal vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine, 13-valent [Adsorbed]), has the potential to provide coverage against the 13 most prevalent serotypes associated with pneumococcal disease (PD), the leading cause of vaccine-preventable death in children younger than five worldwide. (science20.com)
  • Our investigational vaccine, Prevenar 13, builds on the scientific foundation of Prevenar and is designed to provide more comprehensive protection against pneumococcal disease, says Emilio A. Emini, Ph.D., Executive Vice President, Vaccines Research and Development, Wyeth Pharmaceuticals. (science20.com)
  • The introduction of Haemophilus influenzae type b conjugate vaccines during the 1990s was followed by dramatic decreases both in the incidence of Haemophilus influenzae type b related invasive disease and in nasopharyngeal carriage of the organism. (bmj.com)
  • Pneumococcal conjugate vaccine helps protect against bacteria that cause pneumococcal disease. (stylesubstancesoul.com)
  • Adults age 65 or older are amongst the highest risk groups for getting pneumococcal disease. (stylesubstancesoul.com)
  • The pneumococcal vaccine given to older children and adults is thought to be around 50 to 70% effective at preventing pneumococcal disease. (stylesubstancesoul.com)
  • Design, patients and setting: Ecological analysis of trends in invasive pneumococcal disease (IPD) notification rates and vaccine effectiveness estimation using the screening method, using data on Australians aged ≥65 years (23vPPV funded) and 50-64 years (23vPPV not funded). (edu.au)
  • Ludwig E., Bonanni P., Rohde G., Sayiner A., Torres A.. The remaining challenges of pneumococcal disease in adults. (ers-education.org)
  • Clinical presentations and serotypes causing invasive pneumococcal disease in adults vaccinated with the 23-valent polysaccharide pneumococcal vaccine (PPV23) in Spain. (ers-education.org)
  • Too often in the past, new vaccines developed against major diseases such as hepatitis B have waited 10 or even 20 years after their initial licensure to reach those in low-income countries where disease burden tends to be highest. (vaccinealliance.org)
  • BACKGROUND: People with HIV (PWH) are at increased risk for invasive pneumococcal disease (IPD). (cdc.gov)
  • The company is developing its pneumococcal vaccine for treating invasive diseases and otitis media in healthy infant populations. (medgadget.com)
  • These vaccines have been extensively studied, are currently in human trial phase 1/2, and seem to be the best treatment choice for pneumococcal diseases, especially for developing countries. (mdpi.com)
  • For more than 100 years, Merck has contributed to the discovery and development of novel medicines and vaccines to combat infectious diseases. (merck.com)
  • For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. (merck.com)
  • What diseases does pneumococcal vaccine prevent? (stylesubstancesoul.com)
  • These vaccines prevent infections in children who get them, and help stop the infections from spreading to others. (kidshealth.org)
  • Children younger than 2 years old, adults over 65, and people with some medical conditions are at high risk for serious pneumococcal infections. (kidshealth.org)
  • In the US, pneumococcal pneumonia, meningitis, and bloodstream infections (sepsis) kill tens of thousands each year, including thousands of adults age 65 years and older. (nfid.org)
  • Pneumococcal bloodstream infections can be deadly. (nfid.org)
  • Unconjugated as well as conjugated pneumococcal polysaccharide vaccines have been used with success for reducing the rate of pneumococcal infections, especially in adults and children. (medgadget.com)
  • yet, the number of people who plan on getting the vaccines for each of the infections remains low, according to the NFID announcement today. (infectioncontroltoday.com)
  • Several new mucosal vaccines against respiratory infections are under development. (bmj.com)
  • The routine use of PCV7 in infants and young children resulted in significant reductions in IPD caused by vaccine serotypes in children, and because of indirect effects, also in adults. (cdc.gov)
  • Rates of IPD caused by vaccine serotypes in adults aged 18-64 years without HIV decreased from six cases to one case per 100,000 during 2000-2007. (cdc.gov)
  • Pneumococcal meningitis can be deadly. (nfid.org)
  • People who survive pneumococcal meningitis can suffer from devastating health problems like hearing loss, seizures, blindness, and paralysis. (nfid.org)
  • Pneumococcal vaccines can prevent some cases of pneumonia, meningitis, and sepsis. (cnshealthcare.com)
  • Pneumococcal meningitis is an infection of the tissue covering the brain and spinal cord. (cnshealthcare.com)
  • They have poor antibody responses to polysaccharide antigens but elevated levels of serum immunoglobulin A (IgA) and immunoglobulin E (IgE) with low levels of immunoglobulin M (IgM). (medscape.com)
  • Overview of Immunization Immunity can be achieved Actively by using antigens (eg, vaccines, toxoids) Passively by using antibodies (eg, immune globulins, antitoxins) A toxoid is a bacterial toxin that has been modified. (merckmanuals.com)
  • Particularly, their initiatives have facilitated the development of potential vaccine antigens. (medgadget.com)
  • This aside, increasing trend of antibiotic resistance has spurred research in pneumococcal vaccines that can cover against wide range of pneumococci antigens. (medgadget.com)
  • The new generation of whole-cell vaccines is based on an unencapsulated serotype that allows the expression of many bacterial antigens at a lower cost than a recombinant vaccine. (mdpi.com)
  • This article reviews recent studies on mucosal immune responses induced by polysaccharide based vaccines and some protein vaccine antigens against several pathogenic nasopharyngeal bacteria, and discusses the mechanisms and functions of these immune responses that may help our understanding of mucosal immune responses to both immunisation and infection. (bmj.com)
  • Immunogenicity of three versus four doses of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in allogeneic haematopoietic stem cell transplantation recipients: a multicentre, randomized controlled trial. (bvsalud.org)
  • Studies assessing the safety, immunogenicity, and efficacy of pneumococcal conjugate vaccines in both healthy and high-risk 6 - 17-year-old children and adolescents are covered and the potential impact of PCV-13 in these populations is discussed. (uzh.ch)
  • The successful deployment of live attenuated influenza vaccines depends on ensuring an appropriate balance between attenuation and immunogenicity. (who.int)
  • Immunogenicity, vaccine response monitoring, and requirements for additional booster doses for patients with HIV are discussed on pages for individual vaccines. (hivguidelines.org)
  • Vaccine-mediated immunity is "conferred mainly by opsonophagocytic killing of S. pneumoniae. (wikipedia.org)
  • Based on their thick layer of capsular polysaccharide (CPS), S. pneumoniae have been classified into about 97 different specific types according to the Danish classification system [ 2 , 3 ]. (mdpi.com)
  • Pneumovax 23, Merck & Co. Inc.), the vaccine currently recommended for these groups of adults ( 1 ). (cdc.gov)
  • Since 2006, WHO has recommended that all countries incorporate pneumococcal conjugate vaccines in routine immunization schedules for children aged less than two years with priority being given to their introduction in countries with high child mortality rates and/or high rates of HIV infection. (who.int)
  • However, two types of vaccines are available to help prevent infection with the most common strains. (who.int)
  • Hypersensitivity to the active substances, to any of the excipients listed in section 6.1 of the VAXNEUVANCE SmPC, or to any diphtheria toxoid containing vaccine. (msdconnect.co.uk)
  • Despite the broader serotype coverage of PPV-23, the benefits of this vaccine in high-risk populations are uncertain. (uzh.ch)
  • However, serotype replacement, i.e. replacement of vaccine serotypes by non-vaccine serotypes, has decreased the serotype coverage of PCVs over time [ 6 , 7 ]. (ersjournals.com)
  • Vaccine-serotype-coverage was estimated. (bvsalud.org)
  • In the light of rapidly aging populations in low and middle-income countries, vaccine manufacturers have focused on vaccine efficacy, apart from cost effectiveness. (medgadget.com)
  • In recent decades, shifting serotype dominance has led pharmaceuticals to doubt the efficacy of polysaccharide vaccine. (medgadget.com)
  • The primary objective of the study was to evaluate the efficacy of the EV71 vaccine in the prevention of HFMD caused by EV71 in infants of between 6 to 35 months of age. (sinovac.com)
  • With knowledge of this unmet need, we commenced development of an EV71 vaccine in 2008, and recently concluded the phase III efficacy trial for this candidate. (sinovac.com)
  • In March 2013, the unblinded top-line results from the phase III clinical trial for the vaccine demonstrated a 95% efficacy rate against HFMD caused by EV71. (sinovac.com)
  • Our well-trained, experienced sales team continues to drive growth in our commercialized vaccine products, but also has taken significant strides to increase efficacy in our sales and marketing infrastructure, positioning us well for future vaccine product launches, such as the EV71 vaccine. (sinovac.com)
  • PCV7 vaccine - containing an antigen from 7 of the most common capsular types (4, 6B, 9V, 14, 18C, 19F, 23F) was introduced into the routine primary immunisation schedule in September 2008, with a catch up programme for children under 2 years of age. (hse.ie)
  • Conjugate vaccine technology, where a polysaccharide antigen is coupled chemically to a protein carrier, either by direct linkage or by indirect coupling via diamino spacer molecules, can render the PS specific immune response T cell dependent. (bmj.com)
  • Conducted in a country without routine pneumococcal conjugate vaccine (PCV) use, allowing inclusion of an unvaccinated control group and measurement of the reduction in carriage afforded by the reduced-dose schedules. (bmj.com)
  • This replaced PCV 7 (Prevenar 7) the pneumococcal conjugate vaccine introduced into the routine childhood immunisation programme in September 2008. (hse.ie)
  • Prevenar 13 did not affect responses to the concomitantly administered vaccine and showed a safety profile comparable to Prevenar. (science20.com)
  • Title : Pneumococcal polysaccharide 15-valent conjugate vaccine (V114, VAXNEUVANCE) : pediatric clinical development program Personal Author(s) : Banniettis, Natalie Corporate Authors(s) : Merck Research Laboratories. (cdc.gov)
  • A case in point is Merck developing 15-valent pneumococcal conjugate vaccine candidate, V114. (medgadget.com)
  • KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the company has submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for licensure of V114, Merck's investigational 15-valent pneumococcal conjugate vaccine, for use in adults 18 years of age and older. (merck.com)
  • These vaccines can prevent or reduce the severity of pneumococcal pneumonia, a very common cause of bacterial pneumonia. (healthinaging.org)
  • Two types of available vaccines help protect against different strains of a common variety of bacterial pneumonia . (medicalnewstoday.com)
  • Currently available PCVs are safe and efficacious and the increased number of serotypes present in these vaccines, compared to the first licensed PCV7, represent significant progress in the fight against pneumococcal morbidity and mortality, in particular from a developing country perspective. (who.int)
  • Introduction Reduced-dose schedules offer a more efficient and affordable way to use pneumococcal conjugate vaccines (PCVs). (bmj.com)
  • Each dormi- droplets and is a leading cause of vaccine-preventable tory contained multiple large rooms with 4-6 rows of illness and death ( 2 ). (cdc.gov)
  • With hopes running high for a new vaccine against the major killer pneumococcus, the Alliance partners are tackling the tough challenge of making sure it will be promptly available and affordable in developing countries. (vaccinealliance.org)
  • But a vaccine can only save lives if it is accessible and this is the second reason why pneumococcus is coming under the spotlight now. (vaccinealliance.org)
  • For patients with HIV and CD4 counts ≥200 cells/mm 3 , inactivated forms of vaccines such as those for polio, influenza, typhoid, and zoster are preferred over the live vaccine options. (hivguidelines.org)
  • Looking at the shot record, please tell me how many times {Child's name} has received a polio vaccine by mouth (pink drops) or a polio shot? (cdc.gov)
  • Further, aluminum is also added to the vaccine serum because it is an adjuvant, meaning it further enhances the immune response. (wikipedia.org)
  • Protein dose-sparing effect of AS01B adjuvant in a randomized preventive HIV vaccine trial of ALVAC-HIV (vCP2438) and adjuvanted bivalent subtype C gp120. (amedeo.com)
  • It contains purified capsular polysaccharide of pneumococcal serotypes conjugated to a carrier protein to improve antibody response compared to the pneumococcal polysaccharide vaccine. (wikipedia.org)
  • Pneumococcal Vaccine clinical trials, like those at CNS Healthcare, can help you explore new vaccine options. (cnshealthcare.com)
  • Find out more about enrolling pneumococcal vaccine clinical trials available by selecting one of the below locations near you. (cnshealthcare.com)
  • Pneumonia vaccines are recommended for adults and children for a wide range of clinical conditions. (medgadget.com)
  • For more than a century, Merck inventors have developed vaccines that help tackle some of society's biggest public health challenges, and that heritage is reflected today in our pneumococcal vaccine portfolio," said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. (merck.com)
  • The purpose of the revised recommendations is to provide vaccine manufacturers and national regulatory authorities with guidance on the specific processes for production and control of human, live attenuated influenza vaccines, plus guidance on the nonclinical and clinical evaluation of such vaccines. (who.int)
  • The National Vaccine Injury Compensation Program covers all seasonal influenza vaccines, including trivalent and quadrivalent influenza vaccines. (hrsa.gov)
  • The National Vaccine Injury Compensation Program does not cover other non-seasonal influenza vaccines that are used in connection with a pandemic, such as the H1N1 monovalent vaccine that was administered in 2009 during a worldwide outbreak of H1N1 or bird flu. (hrsa.gov)
  • Some non-seasonal influenza vaccines, however, are covered by the Countermeasures Injury Compensation Program (CICP) . (hrsa.gov)
  • The continuing development and public health use of influenza vaccines made from live attenuated influenzavirus strains made it appropriate to review and update the WHO recommendations for such vaccines. (who.int)
  • Growing focus of NGOs and global agencies on pneumonia prevention strategies has augmented the role of vaccines. (medgadget.com)
  • and Flucelvax, the first cell-culture derived influenza vaccine approved in the U.S., designed to protect adults 18 years and older against seasonal flu. (genengnews.com)
  • At the heart of the VaxArray Pneumococcal Assay Kit are simple microarrays, each of which contains 24 serotype-specific monoclonal antibodies for high priority pneumococcal capsular polysaccharide serotypes present in a variety of both on-market and in-development pneumococcal vaccines. (indevr.com)
  • The general CDC guidelines for people who are 65 years of age or older vary, depending on the type of vaccine. (medicalnewstoday.com)
  • This type of vaccine has been occupying sizable shares in the market. (medgadget.com)
  • Objective: To evaluate the impact and effectiveness of the 23-valent polysaccharide pneumococcal vaccine (23vPPV) in ≥65-year-old Australians in the context of concurrent 7-valent pneumococcal conjugate vaccine (7vPCV) use in infants. (edu.au)
  • Greater reductions in IPD in ≥65-year-olds would be expected from the indirect effects of using 13-valent pneumococcal conjugate vaccine in infants (introduced for Australian infants in 2011) and an increase in 23vPPV coverage. (edu.au)
  • In addition to a combined portfolio of vaccines and antibacterial, antiviral and antifungal medicines, Merck has multiple programs that span discovery through late-stage development. (merck.com)